Targeted glypican-3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA

详细信息    查看全文

• 作者：Dandan Yu (1)
  Zhizhen Dong (2)
  Min Yao (3)
  Wei Wu (1)
  Meijuan Yan (3)
  Xiaodi Yan (4)
  Liwei Qiu (1)
  Jie Chen (4)
  Wenli Sai (1)
  Dengfu Yao (1)
  
• 关键词：Hepatocellular carcinoma ; Glypican ; 3 ; shRNA ; Transfection ; Gene silencing
• 刊名：Tumor Biology
• 出版年：2013
• 出版时间：April 2013
• 年：2013
• 卷：34
• 期：2
• 页码：661-668
• 全文大小：392KB
• 参考文献：1. Tang YH, Wen TF, Chen X. Resection margin in hepatectomy for hepatocellular carcinoma: a systematic review. Hepatogastroenterology. 2012;59(117):1393-.
  2. Melloul E, Lesurtel M, Carr BI, Clavien PA. Developments in liver transplantation for hepatocellular carcinoma. Semin Oncol. 2012;39(4):510-1. CrossRef
  3. Shen YC, Hsu C, Cheng CC, Hu FC, Cheng AL. A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression. Oncology. 2012;82(5):275-9. CrossRef
  4. Tazi el M, Essadi I, M'rabti H, Touyar A, Errihani PH. Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma. N Am J Med Sci. 2011; 3(4): 167-5 [PMID:22540086]
  5. Cao H, Phan H, Yang LX. Improved chemotherapy for hepatocellular carcinoma. Anticancer Res. 2012;32(4):1379-6.
  6. Wu Q, Liu Q. Do hepatitis B virus and hepatitis C virus co-infections increase hepatocellular carcinoma occurrence through synergistically modulating lipogenic gene expression? Hepatol Res. 2012;42(8):733-0. CrossRef
  7. Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology. 2007;72(1):30-4. CrossRef
  8. Wysocki PJ. Targeted therapy of hepatocellular cancer. Expert Opin Investig Drugs. 2010;19(2):265-4. CrossRef
  9. Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol. 2010;80(5):550-0. CrossRef
  10. Finn RS. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin Cancer Res. 2010;16(2):390-. CrossRef
  11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-4. CrossRef
  12. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clément B, Balabaud C, Chevet E, Laurent A, Couchy G, Letouzé E, Calvo F, Zucman-Rossi J. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012;44(6):694-. CrossRef
  13. Capurro MI, Shi W, Sandal S, Filmus J. Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma growth. J Biol Chem. 2005;280(50):41201-. CrossRef
  14. Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005;65(14):6245-4. CrossRef
  15. Zittermann SI, Capurro MI, Shi W, Filmus J. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer. 2010;126(6):1291-01.
  16. Kandil DH, Cooper K. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol. 2009;16(2):125-9. CrossRef
  17. Yao M, Yao DF, Bian YZ, Zhang CG, Qiu LW, Wu W, Sai WL, Yang JL, Zhang HJ. Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2011;10(3):289-4. CrossRef
  18. Bian YZ, Yao DF, Zhang CG, Li SS, Wu W, Dong ZZ, Qiu LW, Yu DD. Expression features of glypican-3 and its diagnostic and differential values in hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi. 2011;19(4):260-.
  19. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118-7. CrossRef
  20. Frenette C, Gish RG. Hepatocellular carcinoma: molecular and genomic guideline for the clinician. Clin Liver Dis. 2011;15(2):307-1. CrossRef
  21. Gonzalez SA, Keeffe EB. Diagnosis of hepatocellular carcinoma: role of markers and liver biopsy. Clin Liver Dis. 2011;15(2):297-06. CrossRef
  22. DuBray Jr BJ, Chapman WC, Anderson CD. Hepatocellular carcinoma: a review of the surgical approaches to management. Mo Med. 2011;108(3):195-.
  23. Esheba GE, Pate LL, Longacre TA. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary. Am J Surg Pathol. 2008;32(4):600-. CrossRef
  24. Filmus J, Capurro M. The role of glypican-3 in the regulation of body size and cancer. Cell Cycle. 2008;7(18):2787-0. CrossRef
  25. Lai JP, Oseini AM, Moser CD, Yu C, Elsawa SF, Hu C, Nakamura I, Han T, Aderca I, Isomoto H, Garrity-Park MM, Shire AM, Li J, Sanderson SO, Adjei AA, Fernandez-Zapico ME, Roberts LR. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation. Hepatology. 2010;52(5):1680-. CrossRef
  26. Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T, Nakatsura T. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci. 2009;100(8):1403-. CrossRef
  27. Nassar A, Cohen C, Siddiqui MT. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies. Diagn Cytopathol. 2009;37(9):629-5. CrossRef
  28. Kandil D, Leiman G, Allegretta M, Trotman W, Pantanowitz L, Goulart R, Evans M. Glypican-3 immunocytochemistry in liver fine-needle aspirates: a novel stain to assist in the differentiation of benign and malignant liver lesions. Cancer. 2007;111(5):316-2. CrossRef
  29. Huang N, Lin J, Ruan J, Su N, Qing R, Liu F, He B, Lv C, Zheng D, Luo R. MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3. FEBS Lett. 2012;586(6):884-1. CrossRef
  30. Liu S, Li Y, Chen W, Zheng P, Liu T, He W, Zhang J, Zeng X. Silencing glypican-3 expression induces apoptosis in human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2012;419(4):656-1. CrossRef
  31. Sun CK, Chua MS, He J, So SK. Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2. Neoplasia. 2011;13(8):735-7.
  32. Suzuki M, Sugimoto K, Tanaka J, Tameda M, Inagaki Y, Kusagawa S, Nojiri K, Beppu T, Yoneda K, Yamamoto N, Ito M, Yoneda M, Uchida K, Takase K, Shiraki K. Up-regulation of glypican-3 in human hepatocellular carcinoma. Anticancer Res. 2010;30(12):5055-1.
  33. Qian J, Yao D, Dong Z, Wu W, Qiu L, Yao N, Li S, Bian Y, Wang Z, Shi G. Characteristics of hepatic igf-ii expression and monitored levels of circulating igf-ii mRNA in metastasis of hepatocellular carcinoma. Am J Clin Pathol. 2010;134(5):799-06. CrossRef
  34. Wu W, Yao D, Wang Y, Qiu L, Sai W, Yang J, Yao N, Li S, Bian Y, Wang Z, Yao D. Suppression of human hepatoma (HepG2) cell growth by nuclear factor-kappaB/p65 specific siRNA. Tumour Biol. 2010;31(6):605-1. CrossRef
  35. Lee YL, Ahn BC, Lee Y, Lee SW, Cho JY, Lee J. Targeting of hepatocellular carcinoma with glypican-3-targeting peptide ligand. J Pept Sci. 2011;17(11):763-. CrossRef
  36. Dong ZZ, Yao DF, Wu W, Yao M, Yu HB, Shen JJ, Qiu LW, Yao NH, Sai WL, Yang JL. Delayed hepatocarcinogenesis through antiangiogenic intervention in the nuclear factor-kappa B activation pathway in rats. Hepatobiliary Pancreat Dis Int. 2010;9(2):169-4.
  
• 作者单位：Dandan Yu (1)
  Zhizhen Dong (2)
  Min Yao (3)
  Wei Wu (1)
  Meijuan Yan (3)
  Xiaodi Yan (4)
  Liwei Qiu (1)
  Jie Chen (4)
  Wenli Sai (1)
  Dengfu Yao (1)
  
  1. Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, 20 West Temple Road, Nantong, 226001, Jiangsu Province, China
  2. Department of Diagnostics, Medical School of Nantong University, 19 Qixiu Road, Nantong, 226001, Jiangsu Province, China
  3. Medical School, Nantong University, 19 Qixiu Road, Nantong, 226001, Jiangsu Province, China
  4. Institute of Clinical Oncology, Affiliated Hospital of Nantong University, 20 West Temple Road, Nantong, 226001, Jiangsu Province, China
  
• ISSN：1423-0380

文摘

Hepatocellular carcinoma (HCC) is a highly chemoresistant cancer with no effective systemic therapy. Despite of surgical or locoregional therapies, prognosis remains poor because of high tumor recurrence or progression, and currently, there are no well-established effective adjuvant therapies. Glypican-3 (GPC-3) is specifically overexpressed in hepatoma and perhaps is a valuable molecular target for HCC therapy. In this present study, the effect of silencing GPC-3 gene transcription on human HepG2 cell proliferation was investigated by constructing GPC-3 short hairpin RNA (shRNA) plasmid. After HepG2 cells were transfected with the most efficient shRNA, GPC-3 mRNA expression (90.4?%) was inhibited significantly and estimated by fluorescence quantitative reverse transcriptase-polymerase chain reaction, and the result was accordance with downregulation at the protein level. The percentage of the cell proliferation was down to 28.9?% in the shRNA group and 19.9?% in the shRNA plus sorafenib group. The cell cycles were arrested in the G1 phase (65.6?%) and the apoptosis rate was increasing (66.75?%) in the shRNA1 group with significant alteration compared with that in the negative-shRNA group. Specific shRNA might intervene effectively GPC-3 activation and inhibit tumor cell proliferation, suggesting that GPC-3 gene should be a potential molecular target for HCC therapy.